VANCOUVER, British Columbia, March 14, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports it is granting 3,375,000 incentive stock options to officers, directors and consultants of the Company, exercisable at $0.54 per share for five years, of which 650,000 will expire in two years and will be subject to vesting provisions.
In addition, the Company reports that Thomas Clarke has resigned as a Director of the Company. The Company thanks Mr. Clarke for his contributions and wishes him well in his future endeavours.
The Company has engaged InvestorsHub.com Inc. (“InvestorsHub”) for news release dissemination services for a fee of $20,000 USD effective May 14, 2025 until the budget is exhausted. The Company may elect to renew the engagement in the future. Consideration paid to InvestorsHub does not include any securities of the Company (address: PO Box 780, Harrisonville, MO 6470, 888-498-5839).
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…